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Summary 
Background: The extent of intentional or accidental subcutaneous and intramuscular injections 
and the factors associated with these have rarely been studied among people who inject 
drugs, yet these may play an important role in the acquisition bacterial infections. This study 
describes the extent of these, and in particular the factors and harms associated with 
accidental subcutaneous and intramuscular injections (i.e. ‘missed hits’). 
Method: People who inject drugs were recruited using respondent driven sampling. Weighted 
data was examined using bivariate analyses and logistic regression. 
Results: The participants mean age was 33 years (31% aged under 30-years), 28% were 
women, and the mean time since first injection was 12 years (N=329). During the preceding 
three months, 97% had injected heroin, 71% crack-cocaine, and 16% amphetamines; 36% 
injected daily. Overall, 99% (325) reported that they aimed to inject intravenously; only three 
aimed to inject subcutaneously and one intramuscularly.  Of those that aimed to inject 
intravenously, 56% (181) reported ever missing a vein (for 51 this occurred more than four 
times month on average). Factors associated with ‘missed hits’ suggested that these were the 
consequence of poor vascular access, injection technique and/or hygiene.  ‘Missed hits’ were 
twice as common among those reporting sores/open wounds, abscesses, or redness, swelling 
& tenderness at injection sites. 
Conclusions:  Intentional subcutaneous and intramuscular injections are rare in this sample. 
‘Missed hits’ are common and appear to be associated with poor injection practice. 
Interventions are required to reduce risk through improving injecting practice and hygiene. 
 
Word count: 247. 
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Introduction 
People who inject psychoactive drugs (such as heroin, cocaine and amphetamine) normally 
aim to inject intravenously, but often have difficulty with venous access either as a result of 
poor injection technique or because of the vascular damage that can occur over time when 
injecting regularly (Rhodes, Stoneman, Hope, Hunt, & Judd, 2006; Rhodes, Briggs, Kimber, 
Jones, & Holloway, 2007; Harris & Rhodes, 2012).  As a result they may have to make several 
injection attempts to gain venous access or use multiple areas of the body for injection (Darke, 
Ross, & Kaye, 2001; Maliphant & Scott, 2005; Harris & Rhodes, 2012).  This difficulty with 
vascular access can result in accidental subcutaneous and intramuscular injections – ‘missed 
hits’ (Hankins , Palmer, & Singh, 2000; Rhodes, Briggs, Kimber, Jones, & Holloway, 2007).  In 
addition, for some people who inject psychoactive drugs (and also for those people who inject 
image and performance enhancing drugs, such as anabolic steroids and melanotan) their 
usual injection practice will be subcutaneous (‘Skin Popping’) or intramuscular (‘Muscle 
Popping’) (Binswanger, Kral, Bluthenthal, & Rybold, 2000; Pirozzi, Van, Pontious, & Meyr, 
2014; Hope, et al., 2015).  
 
Intentional or accidental subcutaneous and intramuscular injections among people who inject 
psychoactive drugs are known to be a risk factor for injection related bacterial infections 
(Binswanger, Kral, Bluthenthal, & Rybold, 2000; Pirozzi, Van, Pontious, & Meyr, 2014), 
particularly those caused by anaerobic organisms, such as, wound botulism and tetanus 
(CDC, 1995; Brett, Hood, Brazier, Duerden, & Hahne, 2005; Palmateer, et al., 2013). 
Injections under the skin and into the muscle, particularly if they are accidental, could cause 
physical damage to tissues as a result of poor injection technique (Nicoll & Hesby, 2002; 
Ogston-Tuck, 2014). In addition, the two most commonly injected psychoactive drugs in the 
United Kingdom, brown heroin and crack-cocaine, both need to be dissolved in acidic 
solutions (Scott, Winfield, Kennedy, & Bond, 2000; Scott & Ponton, 2004).  These acidic 
solutions when injected into vascular system are likely to be quickly diluted, but if injected 
under the skin or into the muscle (either during intentional subcutaneous and intramuscular 
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injections or due to a ‘missed hit’) they could cause injecting site problems through chemical 
irritation and damage to these soft tissues (Lake & Beecroft , 2010). 
 
The extent of subcutaneous and intramuscular injections, including ‘missed hits’, and the 
factors associated with these have very rarely been studied.  Several studies in the western 
USA, have reported on subcutaneous and intramuscular injections among people who inject 
drugs, though not on whether these injections were intentional or accidental. In a study from 
1997 conducted in San Francisco, California, 22% reported subcutaneous or intramuscular 
injections in the previous 30 days (Binswanger, Kral, Bluthenthal, & Rybold, 2000), and a 
more recent study from 2003-2005 indicated these practices were also common in Los 
Angeles, Oakland, and Berkeley, California, but didn’t report on their extent (Fink, Lindsay, 
Slymen, Kral, & Bluthenth, 2013).  In a third study undertaken during 2010 in Seattle, 
Washington, 56% had ever injected intramuscularly (Coffin, Coffin, Murphy, Jenkins, & 
Golden, 2012). However, the extent of these practices in the western USA may, in part at 
least, be related to the injection of ‘black tar’ heroin and the particular problems associated the 
use of this drug (Coffin, Coffin, Murphy, Jenkins, & Golden, 2012), thus limiting the 
generalisability of these findings other areas with different patterns of drug use. 
 
Considering the extent of injecting site infections among people who inject drugs in the United 
Kingdom (Hope, Kimber, Hickman, Vickerman, & Ncube, 2008), in particular the substantial 
and ongoing problems with wound botulism and tetanus (Palmateer, et al., 2013; Anon, 2015), 
data on the extent of, and the harms associated with, both intentional and accidental 
subcutaneous and intramuscular injections among this population are needed to help inform 
public health responses.  Our study aimed to address this knowledge gap by asking 
participants about intentional subcutaneous or intramuscular injections and also about ‘missed 
hits’. This paper describes:- a) the extent of subcutaneous injections, intramuscular injections, 
and ‘missed hits’; b) the factors associated with reporting a ‘missed hit’; and c) the extent of 
symptoms of injection site infections and injuries among those who report ‘missed hits’. 
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Methods 
People who inject drugs were recruited into a voluntary unlinked-anonymous cross-sectional 
survey in Bristol, a major urban area in the south west of England, United Kingdom, using 
respondent driven sampling (RDS) during the September and October of 2009. RDS is an 
established recruitment process which has been explained fully elsewhere (Salganik & 
Heckathorn, 2004; Heckathorn D. , 1997; Heckathorn D. , 2002). Briefly, RDS starts with the 
selection of the initial recruits, or ‘seeds’, with further subjects then recruited through the 
participant’s social networks. The ‘seeds’ (n=10) were selected in relation to location and 
gender through key informant referrals and street outreach. To be eligible, participants had to 
be aged over 15-years, have injected drugs during the preceding four weeks, live within the 
Bristol urban area (population: urban area 617,000; city 432,500) and give consent.  
 
Participants provided a dried blood spot (DBS) sample (which was tested for antibodies to HIV 
[anti-HIV], the hepatitis B core antigen [anti-HBc], and the hepatitis C virus [anti-HCV]), 
underwent a computer-assisted interview, and were then offered an acknowledgement. 
Participants were then asked to act as recruiters, and those who agreed to this were given 
three uniquely numbered and date-limited coupons. They were instructed to give these 
coupons only to eligible individuals whom they knew and received a further acknowledgement 
for each coupon that led to a successful participation. A single fieldwork co-ordinator screened 
all participants for eligibility and also for attempted repeat participations. The study had ethical 
approval (London REC, MREC/98/2/51). 
 
The questionnaire used in the study was developed from ones that had previously been used 
with people who inject drugs in the United Kingdom (Judd, et al., 2005; Hickman, et al., 2007; 
Hickman, et al., 2009; Hope, Ncube, Parry, & Hickman, 2015).  The questions on injection 
technique were developed from the existing questions about injecting practice. Participants 
were asked “How do you usually try to inject?” with answer options “In to a vein”, ”Under the 
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skin - Skin Popping”, or “In to the Muscle - Muscle Popping”.  Those injecting into vein were 
then asked if they had missed the vein when trying to inject and how often this occurred. The 
questionnaire was reviewed by members of the study team, including the fieldworkers, and by 
people working with people who inject drugs in the study area.  The two main foci were: 1) 
injecting drug use (drugs used, paraphernalia used and injection practices); and 2) health 
harms (particularly infections) and uptake of health care related interventions.  In addition, the 
questionnaire asked about demographics, environmental factors (such as contact with the 
criminal justice system and homelessness), and sexual behaviours.  
 
In RDS studies there is a tendency for participants’ to recruit people like themselves, and a 
higher probability that people with large networks will be recruited.  For example, in our survey 
people who inject drugs who had been homeless in the last year had larger networks than 
those who had not, and recruited proportionally more people who were also homeless. 
RDSTAT software (Version 5.4.0. Ithaca, New York: Volz E, Heckathorn DD; 2005) was used 
to test for evidence of selection bias and to generate sample derived weights; with age-group, 
homelessness and crack injection used to weight the data for analysis.   
 
Weighted data were used in all of the analyses, which were undertaken using SPSS 19. First, 
bivariate associations between reporting a ‘missed hit’ and demographic characteristics, 
environmental factors, the drugs used, and injecting practices were examined using the χ2 
test. The environmental, drug use and injecting practice variables used in the analyses were 
for factors that had been shown in previous studies of either injecting risk practice or bacterial 
infections among people who inject drugs to be related to those outcomes (Hickman, et al., 
2007; Hope, Kimber, Hickman, Vickerman, & Ncube, 2008; Salmon, Dwyer, Jauncey, van 
Beek, Topp, & Maher, 2009). Those characteristics found to be associated in the bivariate 
analyses were entered using the forward stepwise procedure in SPSS into a logistic 
regression model with inclusion assessed using the likelihood ratio (with the stepwise 
probability for inclusion of 0.05 and exclusion of 0.1). 
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Finally, considering that ‘missed hits’ may be a factor in the development of injecting site 
problems, the extent of symptoms of injection site infections or injuries among those who had 
aimed to inject intravenously were examined.  Associations between these symptoms and 
reporting ‘missed hits’ were examined using the χ2 test and logistic regression to adjust for 
possible confounding variables.  In addition, associations were then examined using the χ2 
test between the frequency of reporting ‘missed hits’ and, a) symptoms of injection site 
infections and injuries, and b) seeking healthcare in response to these symptoms. 
 
Results 
Demographic and drug use characteristics. 
Questionnaires were obtained from 329 individuals, weight characteristic a summarised in 
table 1. Briefly, their mean age was 33 years, one quarter were women, and half had been 
homeless during the preceding year. The mean time since they had first injected drugs was 12 
years, almost all had injected heroin during the preceding three months and nearly three-
quarters had injected crack-cocaine. Two-thirds were receiving a detox or maintenance drug 
regime, such as opiate substitution therapy, and half reported that they had ever cleaned and 
then re-used needles and/or syringes. 
 
Injection technique. 
Overall, 99% (n=325) reported that the usually aimed to inject intravenously (table 1), with 
only three participants reporting that they usually injected subcutaneously (i.e. under the skin 
or ‘skin popping’) and one reporting they usually injected intramuscularly (i.e. in to the muscle 
or ‘muscle popping’). The four that did not usually aim to inject intravenously were all male, 
they were older (mean age of 44 years, median 43, vs. mean age of 33 years, median 33) and 
had been injecting for longer (mean time since first injection of 20 years, median 21, vs. mean 
time of 12 years, median 12).   
 
Missed hits among in drug users. 
8  
Of those who usually aimed to inject intravenously, over half (56%, n=181) reported that they 
had ever missed a vein, that is accidentally injected subcutaneously or intramuscularly (a 
‘missed hit’). Of those who had ever missed a vein, 51% (n=92) reported that this happened 
less than once a month, for 21% (n=38) this typically happened between one and four times a 
month, and for 28% (n=51) ‘missed hits’ occurred more frequently. Reporting having had a 
‘missed hit’ and the frequency of experiencing a ‘missed hit’ were both not associated with 
either age or gender. 
 
Factors associated with ‘missed hits’ among those who aimed to inject intravenously. 
The factors that were found to be associated in both the bivariate and multivariable analyses 
with ‘missed hits’ among the 325 participants who aimed to inject intravenously are shown in 
table 2.  In the multivariate analysis, ever experiencing a ‘missed hit’ (table 2a) was more 
common among those who had been injecting for longer, those who had ever overdosed, 
those injected into their hands (though this was less common among those injecting into their 
groin), those who reported saving filters for reuse, and those who injected more frequently.  
 
Experiencing a missed hit at least monthly (table 2b) was more common in the multivariate 
analysis among those who had inserted the needle three or more times on the last occasion 
that they had injected; those who had shared a needle or syringe; and those who had either 
reused spoons or saved filters.  It also varied by the main area on body used for injecting and 
by the main source of needles and syringes. 
 
Injection site infections and injuries among those aiming to inject intravenously 
Overall of those who aimed to inject intravenously, 62% (n=201) reported ever having had 
redness, swelling & tenderness at an injection site, 44% (n=145) ever having had an abscess, 
and 14% (n=47) ever having had a sore or open wound.  Ever reporting these three symptoms 
of an injection site infection and injury was around twice as common among those who 
reported that they had ever had ‘missed hit’ (table 3). 
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Participants were also asked if they had any of these three symptoms during the preceding 
year; with 41% (n=133) reporting having had redness, swelling & tenderness at an injection 
site during the preceding year, 15% (n=48) an abscess, and 7.4% (n=24) a sore or open 
wound.  The reporting of these symptoms during the preceding year became more common 
as the frequency of having ‘missed hits’ increased (table 4), for example, among those 
reporting no ‘missed hits’ 4.9% reported that they had an abscess during the preceding year, 
this increased to 35% among those who reported having more than four ‘missed hits’ a month.  
 
Those who reported having either an abscess or a sore/open wound at an injection site during 
the preceding year, were also asked if they had sought medical advice about either of these 
two symptoms from a doctor or a nurse (81%, 39/48, and 38%, 9/24, had respectively).  
Reporting having had a ‘missed hit’, and the frequency of experiencing a ‘missed hit’ among 
those who had, were not associated with seeking medical advice from a doctor or a nurse 
about either of these two symptoms during preceding year. 
 
Discussion 
Our findings show that intentional subcutaneous or intramuscular injections are very rare 
among people who inject psychoactive drugs sampled, with these being reported by only 
around one in 100. However, such injections are actually a fairly common occurrence due to 
the ‘missed hits’ that occur when people fail to inject intravenously. Overall, more than half of 
those surveyed reported having had a ‘missed hit’, and for a quarter this happened at least 
once a month, with around one in six reporting having a ‘missed hit’ more than four times a 
month. Those who reported that they had experienced a ‘missed hit’ were twice as likely to 
also report having had symptoms of injection site infections and injuries. 
 
First, it is important to consider the limitations of this study and also the generalizability of its 
findings. The comparative rarity of injecting drug use, its illegal nature, and the marginalisation 
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of those involved are all barriers to the recruitment of a representative sample of people who 
inject drugs. This study aimed to minimize sampling biases and maximize representativeness 
by recruiting the participants through RDS (Heckathorn D. , 1997; Heckathorn D. , 2002; 
Salganik & Heckathorn, 2004) and applying sample derived weights to correct for possible 
recruitment biases; though it is not possible to test how successful this adjustment has been 
(Mills, Johnson, Hickman, Jones, & Colijn, 2014). Even so, RDS is currently regarded as one 
of the most appropriate methods for recruiting community based samples of hidden 
populations, such as, people who inject drugs. Self-reports were used in this study, the 
accuracy of these can be questioned as they are potentially subject to recall bias, however, 
the reliability of self-reported risk behaviours among people who inject drugs has been 
previously shown (Latkin, Vlahov, & Anthony, 1993). The cross-sectional approach used in 
this study allows the exploration of the factors associated with ‘missed hits’; however, it does 
not permit direct examination of causation. Finally, this study recruited participants from a 
single area of England during 2009. The characteristics of the sample recruited here were 
broadly comparable to those of the participants in the United Kingdom’s national bio-
behavioural survey of people who inject drugs during 2009 (Public Health England, 2014.).  
Data from this ongoing annual national survey also indicate that the characteristics and nature 
of psychoactive drug injecting have not change greatly in recent years (Public Health England, 
2014.). Considering these issues the findings should be generalised with some caution. 
 
The extent of having ever injected subcutaneously or intramuscularly, either by intent or by 
accident, in our study was similar to the extent of ever injecting into the muscle found in 
Seattle, USA (Coffin, et al., 2012), but higher than that reported in an study in San Francisco, 
California (Binswanger, Kral, Bluthenthal, & Rybold, 2000). Subcutaneous and intramuscular 
injecting are likely to occur in other populations of people who inject drugs, particular among 
those populations were people have been injecting for long periods (Coffin, et al., 2012). Over 
time these practices, and their associated harms, may become an issue among the ageing 
cohorts of people who inject drugs that are found in many high income countries (European 
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Monitoring Centre for Drugs and Drug Addiction, 2010), where people who have been 
injecting for long periods will be come more common.   
 
The finding that symptoms of injection site infections and injuries were associated with 
reporting a ‘missed hit’, and that these symptoms became more common as the frequency of 
having a ‘missed hit’ increased, corroborate information from case reports, studies of bacterial 
infections among people who inject drugs, and public health surveillance data that indicate 
that a wide range bacterial infections, including Meticillin-resistant Staphylococcus aureus and 
wound botulism, are more common among those who inject subcutaneously or 
intramuscularly (CDC, 1995; Binswanger, Kral, Bluthenthal, & Rybold, 2000; Lowy & Miller, 
2002; Brett, Hood, Brazier, Duerden, & Hahne, 2005; Fink, Lindsay, Slymen, Kral, & 
Bluthenth, 2013; Pirozzi, Van, Pontious, & Meyr, 2014). This probably reflects the damage to 
muscle and other soft tissues that can result from poor injection technique and/or injecting 
acidic solutions, making these injection sites particularly vulnerable to infections by organisms 
introduced during the injection process. When this damage leads to tissue necrosis it can 
result a local environment that is particularly suited to the growth of anaerobic organisms, 
such as the bacteria that cause botulism and tetanus (Brett, Hood, Brazier, Duerden, & 
Hahne, 2005; Palmateer, et al., 2013).  
 
Findings from studies that have looked at both injection site infections and injuries and 
injection practice suggest that a range of factors are associated with the occurrence of these 
problems, and many of these factors indicate that both poor injecting technique and hygiene 
probably play an important role in the development of these largely avoidable harms (Hope, 
Kimber, Hickman, Vickerman, & Ncube, 2008; Salmon, Dwyer, Jauncey, van Beek, Topp, & 
Maher, 2009; Hope, Cullen, Croxford, Parry, & Ncube, 2014). They also indicate that the 
considerable harm caused by these infections and injuries, and the associated costs, can be 
amplified by delays in seeking healthcare (Marks, et al., 2013; Hope, Ncube, Parry, & 
Hickman, 2015).  
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A number of factors were found to be associated with reporting a ‘missed hit’. Of particular 
note are the associations with having injected for longer, injecting into the hands, frequency of 
injection, and inserting the needle multiple times before injecting. These factors are probably a 
reflection of the vascular damage that can occur after injecting frequently over long periods of 
time, particularly if injection technique is poor (Harris & Rhodes, 2012). This vascular damage 
makes accessing peripheral veins difficult, thus making missed hits more likely, but this can 
also result in people using potentially more dangerous injecting sites, such as, the hands, 
neck and groin (Darke, Ross, & Kaye, 2001). There were also associations between reporting 
a ’missed hit’ and aspects of injecting practice – such as the sharing, reuse and saving of 
injecting equipment - that suggest that there may be a wider issue with poor injecting practice 
and hygiene amongst those experiencing ‘missed hits’. 
 
Public health interventions are needed to reduce the occurrence of ‘missed hits’ and the 
associated harms. These should look at ways to support and promote the use of good 
hygienic intravenous injection technique. The findings presented here, and those from 
previous studies undertaken in the United Kingdom (Maliphant & Scott, 2005; Hickman, et al., 
2007; Harris & Rhodes, 2012; Hope, Cullen, Croxford, Parry, & Ncube, 2014), indicate that 
there is considerable room to improve injection practice and hygiene through, for example, 
reducing the reuse of injecting equipment, more consistent cleaning of injections sites and the 
rotation of the body sites used for injection.  Harm reduction responses should therefore 
include the development of interventions to support and promote good injection site 
management (including site rotation, always cleaning sites, always using new sterile 
equipment, and not using excessive acid), so as to minimize vein damage and thus reduce 
the vascular access problems that could lead to ‘missed hits’. These should of course be 
supported by high coverage needle and syringe programmes, distributing a range of 
appropriate injecting equipment, including sterile needles, syringes and swabs (MacArthur, et 
al., 2014).  
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Reporting ‘missed hits’ was less common among those who reported their ‘groin’ (femoral 
vein) as their main injection site. This possibly reflects that successfully injection into the 
femoral vein is easier due to the large size of this vein, which also allows the development of a 
sinus tract (Maliphant & Scott, 2005; Hope, J Scott, Cullen, Parry, Ncube, & Hickman, 2015). 
As a range of potentially serious harms have been associated with the injection into this 
particular body site, including deep vein thrombosis (McColl, Tait, Greer, & Walker, 2001; 
Hope, J Scott, Cullen, Parry, Ncube, & Hickman, 2015), abscesses (Mackenzie, Laing, 
Douglas, Greaves, & Smith, 2000), chronic venous disease (Pieper, Templin, Kirsner, & Birk, 
2009), necrosis of the femoral artery (Mullan, Magowan, & Weir, 2008), septicaemia (Hope, J 
Scott, Cullen, Parry, Ncube, & Hickman, 2015) and hepatitis C infection (Hope, J Scott, 
Cullen, Parry, Ncube, & Hickman, 2015), its use should therefore not be promoted as a way of 
reducing the harms that could result from ‘missed hits’. Instead priority should be given to 
improving injecting technique and vascular care, as well as to interventions to move people 
away injecting. Firstly, this should involve increasing the uptake of opiate substitution therapy 
(MacArthur, et al., 2014), and secondly, if shown to be effective, supporting the use of 
alternative less risky routes of drug administration, such as through providing foil for the 
smoking drugs (Pizzey & Hunt, 2008; Advisory Council on the Misuse of Drugs, 2010).  
 
Conclusions 
This is the first study, to our knowledge, to purposively look at ‘missed hits’, subcutaneous and 
intramuscular injections among a community recruited sample of people who inject drugs.  
Though only about one in 100 reported intentionally injecting subcutaneously or 
intramuscularly; 56% of the participants reported having had a ‘missed hit’, and for a quarter 
this happened at least once a month. The ‘missed hits’ here were associated with having 
injection site infections and injuries, and appeared to be associated with poor injection 
practice. Poor injection technique, and the difficulties with vascular access which can result 
from this, probably play a key role in the occurrence of ‘missed hits’, but this needs further 
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investigation. Interventions to improve injecting technique and hygiene and to help sustain 
access to the peripheral veins are needed. 
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Table 1. Characteristics of the people who inject psychoactive drugs recruited using 
respondent driven sampling, Bristol, United Kingdom. 
All data presented in the table are weighted using sample derived weights. 
 
Characteristic  n % 
Total  329  
Demographics       
Gender 
Male 236 72 
Female 93 28 
Age, years   
(mean age 33 years; 
median 33, IQR 28 to 39) 
<= 29 years 102 31 
30 to 39 years 155 47 
40 years or older 72 22 
Homelessness 
Yes, but not past year 117 36 
Yes, in past year 170 52 
Never 41 13 
Imprisonment 
Never 88 27 
Yes, but not past year 165 50 
Yes, in past year 75 23 
Main Source of 
Income 
Employment 24 7.4 
Social security 210 64 
Street (e.g. begging, selling 'Big Issue', or busking) 18 5.5 
Sex work 15 4.7 
Theft or drug dealing 53 16 
Other or not known 8 2.4 
Recent sexual 
activity 
No sex past year 77 23 
Sex past year, no sex work 228 69 
Sex past year, sex work 24 7.3 
Drug use 
   
Number of years 
since first injected 
(mean 12 years; median 
12, IQR 6 to 17) 
< 5 year 60 18 
5 to 9 years 72 22 
10 to 14 years 76 23 
15 or more years 120 36 
Drugs injected 
during the preceding 
three months 
Heroin 317 97 
Crack-cocaine 233 71 
Powder cocaine 32 10 
Amphetamine 54 16 
Other drugs 14 4.2 
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Table 1 Continued 
 
Injecting practice 
   
Main area on body 
used for injection, 
preceding 28 days 
Hands 15 4.6 
Arms 139 42 
Groin 124 38 
Legs 35 11 
Other 15 4.5 
Washed hands 
before injecting, 
preceding 28 days 
Never 88 27 
Sometimes 86 26 
Always 154 47 
Swabbed injection 
site before injecting, 
preceding 28 days 
Never 67 20 
Sometimes 69 21 
Always 192 59 
Reused spoons/ 
mixing containers, 
preceding 28 days 
Never 56 17 
Sometimes 47 14 
Always 225 68 
Reused filters, 
preceding 28 days 
Never 169 51 
Sometimes 79 24 
Always 81 25 
Have saved filters for reuse 123 37 
Ever clean needles and syringes for reuse 159 48 
Times insert needle 
last time injected 
Once 218 67 
Twice 61 19 
Thrice 22 6.7 
Four or more times 27 8.2 
Tried more than one site on body last time injected 67 20 
Usual injection 
technique 
In to a vein 325 99 
Under the skin – ‘Skin Popping’ 3 0.8 
In to the Muscle – ‘Muscle Popping’ 1 0.2 
       Health services use & intervention uptake 
  
Main source of 
needles and 
syringes 
Specialist needle & syringe programme 129 39 
Pharmacy needle & syringe programme 60 18 
Mobile needle & syringe programme 79 24 
Friends 31 10 
Other people who inject drugs 14 4.3 
Other 14 4.3 
Currently receiving detox or maintenance drug regime  218 66 
Ever had a diagnostic test for HIV 268 82 
Ever had a diagnostic test for hepatitis C 297 90 
Taken up the vaccine against hepatitis B 236 72 
Attended Emergency Department for any reason, preceding year 130 40 
Health Harms    
Had antibodies to hepatitis B core antigen 58 18 
Had antibodies to hepatitis C 186 57 
Had overdosed to the point of losing consciousness  133 41 
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Table 2. Factors associated with ‘missed hits’ among people who aim to inject 
psychoactive drugs intravenously, Bristol, United Kingdom. 
 
Part A:  
Factors associated with ever  
having had missed hit‡‡ 
Reported 
ever having 
a missed hit 
Total Unadjusted Odds Ratio, 
with 95% CI 
Adjusted Odds Ratio, 
with 95% CI 
Total 56% 181 325                 
Number of  
years since  
first injected 
Less than 5 51% 31 60   
 
     
5 to 9 48% 35 72   
 
     
10 to 14 59% 44 75   
 
     
15 or more 61% 72 117   
 
     
 p=0.076**  
 
      
Mean    Yes: 13 No: 11        
per year increase in time since 1st injection 1.03 1.00 - 1.06 1.05 1.01 - 1.08 
 p=0.070
‡  
 
   
 
  
Ever  
overdosed 
No 52% 100 192   
 
 † 
Yes 61% 81 133 1.46 0.93 - 2.29 
 p=0.098  
 
 
    
 
Main area  
on body  
injected into* 
Hands 95% 14 15 9.94 1.01 - 97.6 14.5 1.38 - 152 
Arms 64% 89 138 1.00  
 
 1.00    
Groin 37% 46 124 0.32 0.19 - 0.53 0.24 0.13 - 0.43 
Legs 78% 25 32 1.98 0.80 - 4.89 1.36 0.51 - 3.61 
Other 47% 7 15 0.49 0.17 - 1.42 0.41 0.13 - 1.31 
 p<0.001  
 
      
Reused  
spoons* 
Never 44% 24 56 1.00  
 
 
† Sometimes 52% 24 47 1.37 0.63 - 2.97 
Always 60% 133 222 1.92 1.06 - 3.47 
 p=0.078  
 
 
    
 
Reused  
filters* 
Never 50% 83 167 1.00  
 
 
† Sometimes 59% 45 77 1.43 0.83 - 2.47 
Always 66% 53 81 1.91 1.10 - 3.32 
 p=0.056  
 
 
    
 
Saved  
filters* 
No 50% 103 204 1.00  
 
 1.00    
Yes 65% 79 121 1.82 1.15 - 2.90 1.97 1.15 - 3.40 
 p=0.011  
 
      
Ever cleaned and 
re-used 
needle/syringes 
No 49% 82 168 1.00  
 
 † 
Yes 63% 99 157 1.75 1.12 - 2.73 
 p=0.013  
 
 
    
 
Times  
injected* 
14 or less 46% 35 76   
 
 
    
15 to 28 56% 33 59   
 
 
    
29 to 56 59% 46 78   
 
 
    
57 to 84 60% 30 49   
 
 
    
85 or more 62% 39 63   
 
 
    
 p=0.050   
 
 
    
Mean    Yes: 67 No: 53        
per injection increase in times injected 1.00 1.00 - 1.01 1.00 1.00 - 1.01 
 p=0.057
‡   
 
     
Times insert 
needle last time 
injected 
Once 46% 100 217 1.00  
 
 1.00    
Twice 65% 39 60 2.17 1.20 - 3.93 1.88 0.98 - 3.62 
Thrice 92% 19 21 14.2 2.76 - 73.0 12.4 2.26 - 67.6 
Four or more  87% 24 27 8.12 2.53 - 26.0 5.09 1.51 - 17.2 
  p<0.001                 
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Part B: 
Factors associated with having a 
missed hit at least monthly†††. 
Reported a 
missed hit at 
least 
monthly 
Total Unadjusted Odds Ratio, 
with 95% CI 
Adjusted Odds Ratio, 
with 95% CI 
Total 27% 89 325                 
Main source of 
needles & 
syringes 
Specialist NSP 32% 41 129 1.00    1.00    
Pharmacy NSP 30% 18 60 0.90 0.46 - 1.75 1.32 0.58 - 2.99 
Mobile NSP 24% 19 79 0.68 0.36 - 1.28 0.80 0.37 - 1.74 
Friends 12% 3 30 0.28 0.08 - 0.91 0.31 0.09 - 1.15 
Other PWID 8% 1 14 0.18 0.03 - 1.29 0.12 0.02 - 1.01 
Other 46% 6 13 1.78 0.57 - 5.55 4.02 0.85 - 19.0 
 p=0.059         
Ever had a test 
for hepatitis C 
No 15% 5 31 1.00    † 
Yes 29% 85 294 2.37 0.85 - 6.61 
 p=0.090         
Injected heroin 
during last three 
months 
No 0% 0 11 
 Yes 28% 89 314 
 p=0.039
††         
Main area  
on body  
injected into* 
Hands 29% 4 15 0.70 0.22 - 2.23 0.43 0.10 - 1.93 
Arms 37% 52 138 1.00    1.00    
Groin 15% 18 124 0.29 0.16 - 0.53 0.19 0.09 - 0.41 
Legs 34% 11 32 0.88 0.39 - 1.96 0.58 0.21 - 1.56 
Other 25% 4 15 0.57 0.17 - 1.93 0.69 0.18 - 2.70 
 p=0.002         
Reused  
spoons* 
Never 10% 6 56 1.00    1.00    
Sometimes 21% 10 47 2.33 0.77 - 7.07 4.76 1.26 - 17.9 
Always 33% 74 222 4.32 1.74 - 10.7 6.14 2.05 - 18.4 
 p=0.002         
Reused  
filters* 
Never 21% 35 167     
† Sometimes 26% 20 77 1.30 0.69 - 2.43 
Always 42% 34 81 2.68 1.50 - 4.77 
 p=0.003         
Shared 
needle/syringe* 
No 24% 70 284 1.00    1.00    
Yes 48% 20 41 2.90 1.48 - 5.68 3.07 1.30 - 7.26 
 p=0.001         
Saved filters* 
No 20% 40 204 1.00    1.00    
Yes 41% 49 121 2.79 1.69 - 4.60 2.77 1.50 - 5.12 
 p<0.001         
Ever cleaned and 
re-used 
needle/syringes 
No 21% 34 168 1.00    † 
Yes 35% 55 157 2.08 1.26 - 3.42 
 p=0.004         
Times  
injected* 
14 or less 10% 8 76 1.00    
† 
15 to 28 25% 14 58 2.97 1.14 - 7.74 
29 to 56 35% 28 79 4.86 2.02 - 11.7 
57 to 84 32% 16 49 4.23 1.62 - 11.0 
85 or more 38% 24 63 5.49 2.22 - 13.6 
 p=0.001     
Mean    Yes: 74 No: 56    
per injection increase  1.00 1.00 
 1.01 
 p=0.022
‡   
 
     
Times insert 
needle last time 
injected 
Once 18% 40 217 1.00    1.00    
Twice 29% 18 60 1.84 0.96 - 3.53 1.67 0.78 - 3.59 
Thrice 57% 12 21 5.93 2.33 - 15.1 5.97 1.97 - 18.1 
Four or more  73% 20 27 12.28 4.90 - 30.8 11.0 3.69 - 32.5 
  p<0.001                 
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All data presented in the table are weighted using sample derived weights. 
*  during preceding 28 days.            
†  Not in final model             
**  χ2 for linear trend             
‡  T test             
††  Fisher's Exact Test            
‡‡  No associations (p>0.1) in part A with: Age in years; Gender; Imprisonment; Homelessness; Being prescribed a substitute 
drug; Main source of source needles & syringes; Having had a voluntary confidential test for HIV or hepatitis C; Uptake of the 
hepatitis B vaccine; Attended Emergency Department for any reason preceding year; Having injected during the preceding 3 
months: heroin, crack, powder cocaine, amphetamines, or other drugs; Washing hands before injecting; Swabbing injection 
sites; Sharing needle/syringe; Sex in last year (paid or unpaid). 
†††  No associations (p>0.1) in part B with: Age in years; Gender; Imprisonment; Homelessness; Being prescribed a substitute 
drug; Having had a voluntary confidential test for HIV; Uptake of the hepatitis B vaccine; Attended Emergency Department for 
any reason preceding year; Ever overdosed; Number of years since first injected; Having injected during the preceding 3 
months: crack, powder cocaine, amphetamines, or other drugs; Washing hands before injecting; Swabbing injection sites; 
Sex in last year (paid or unpaid). 
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Table 3. The extent of ever having symptoms of an injecting site infection or injury 
among people who aim to inject psychoactive drugs intravenously that report ever 
having had a ‘Missed hit’, Bristol, United Kingdom. 
 
Reported 
ever having 
a missed hit 
Ever had  
symptom:- 
Total 
(N=325) 
 
Unadjusted Odds 
Ratio, with 95% CI 
Adjusted* Odds 
Ratio, with 95% CI 
  
              
  Abscess 
No  36% 52 144  1.00    1.00    
Yes  51% 93 181 p=0.005 1.89 1.21 - 2.97 2.01 1.19 - 3.39 
              
  Sore or open wound 
No  9.7% 14 144  1.00    1.00    
Yes  18% 33 181 p=0.032 2.04 1.05 - 3.95 2.15 1.02 - 4.54 
              
  Redness, swelling & tenderness 
No  49% 70 144  1.00    1.00    
Yes  72% 131 181 p<0.001 2.72 1.72 - 4.32 2.38 1.43 - 3.96 
                            
 
All data presented in the table are weighted using sample derived weights. 
P values are for Pearson Chi-Square test.  
 * adjusted for years since first injecting, gender, main injection area on body and injection 
frequency. 
 
 
 
 
 
Table 4.  Frequency of ‘missed hits’ and the extent of recent symptoms of an injection 
site infection or injury among people who aim to inject psychoactive drugs 
intravenously, Bristol, United Kingdom. 
 
Had symptom,  
during the 
preceding year 
No missed  
hits 
A missed hit 
less than 
monthly 
A missed hit 
one to four 
times a month 
A missed hit 
more than four 
times a month  
χ2 for 
linear 
trend 
A sore or open 
wound  
3.5% 5 6.5% 6 11% 4 18% 9 p=0.001  
An abscess  4.9% 7 18% 17 16% 6 35% 18 p<0.001  
Redness, 
swelling & 
tenderness 
20% 29 43% 40 61% 23 80% 41 p<0.001  
Total (N=325)   144   92   38   51   
 
All data presented in the table are weighted using sample derived weights. 
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